NILO Therapeutics Funding: $101M Raised, Series A (2025)
NILO Therapeutics is a Biotech company based in New York. It has raised $101M in total funding. Latest round: Series A.
NILO Therapeutics funding overview
NILO Therapeutics is a Biotech company based in New York. NILO Therapeutics has raised $101M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in October 2025. The round record for NILO Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include The Column Group, DCVC Bio, Lux Capital, Gates Foundation, Alexandria Venture Investments. 5 distinct backers are named across the disclosed rounds.
NILO Therapeutics has raised $101M in total disclosed funding across the rounds on record.
Who has invested in NILO Therapeutics?
The Column Group, DCVC Bio, Lux Capital, Gates Foundation, Alexandria Venture Investments are named among the investors backing NILO Therapeutics.
What was the latest NILO Therapeutics funding round?
The most recent disclosed round is a Series A, announced in October 2025.
Where is NILO Therapeutics based?
NILO Therapeutics is based in New York.
What sector does NILO Therapeutics operate in?
NILO Therapeutics is tracked under Biotech from New York, with $101M in disclosed funding.
When did NILO Therapeutics last raise?
The last disclosed NILO Therapeutics round closed in October 2025 at Series A.
Every NILO Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in New York at a similar stage.
